icon-folder.gif   Conference Reports for NATAP  
  HEPDART 2013: Frontiers in Drug Development for Viral Hepatitis
December 8-12, 2013
Big Island, Hawaii
Back grey_arrow_rt.gif
HepDART December 2013 Selected Slide Presentations
  HepDart 2013 December, Hawaii, Selected Slide Presentations
State of the Art Presentation
Innovations in HCV Therapy
Ira Jacobson, Weill Cornell Medical College, USA


Hepatitis C: The Tides Are Shifting
Deploying Nucleoside Therapy to Eradicate HCV John McHutchison, Gilead Sciences Inc., USA
Simeprevir Overview: From IFN-Containing to IFN-Free Regimens Gastˇn Picchio, Janssen R&D, USA
Daclatasvir Present and Future DAA Combinations Douglas Manion, Bristol-Myers Squibb, USA
Efficacy and Resistance Profile of the next Generation Protease Inhibitor MK5172 in IFN-free Phase 2 Studies of GT1 Infection Daria Hazuda, Merck Research Laboratories, USA
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus Infection (HCV) Douglas Mayers, Idenix Pharmaceuticals, Inc., USA
Discovery and Development of a Second Generation Direct-Acting Antiviral Portfolio for Chronic Hepatitis C: An Update on Achillion's Protease Inhibitor (Sovaprevir), NS5A Inhibitor (3102) and Nucleotide Inhibitor (3422) Regimen Strategy David Apelian, Achillion Pharmaceuticals, Inc., USA
The Future of HCV Therapy: Patient-Tailored Treatment or One-Size Fits All? Wulf Otto B÷cher, Boehringer Ingelheim Pharma GmbH & Co KG, Germany
High Sustained Virologic Response Rates with Sofosbuvir Regimens Irrespective of Ribavirin Dose Reductions
Mark Sulkowski, The Johns Hopkins University School of Medicine, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Sulkowski_HepDart Oral Sulkowski_9Dec13_FINAL Tuesday.pdf
Rapid and Consistent Virologic Responses in a Phase 2 Trial of a New All-Oral Combination of Faldaprevir, Deleobuvir
and PPI-668, with and without Ribavirin, in Patients with HCV Genotype-1a Infection
Richard Colonno, Presidio Pharmaceuticals, USA
A Fixed Dose Combination of Sofosbuvir and Ledipasvir is Highly Effective in Treatment-Naïve and Treatment Experienced
Genotype 1 HCV infected Patients: Results from the LONESTAR and ELECTRON Phase 2 Studies
Eric Lawitz, Texas Liver Institute and University of Texas Health Science Center, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Lawitz HEPDART 2013_5Dec13_to client.pdf
Simeprevir with Peginterferon/Ribavirin for Treatment of Chronic HCV Genotype 4 Infection in Treatment-Naïve or -Experienced Patients: Interim Results of a Phase III Trial Christophe Moreno, ULB H˘pital Erasme, Belgium
Lymphomas Associated with HCV Jordan Feld, University of Toronto, Canada http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Feld_MAC NHL Lymphoma & HCV HepDart 2013.pdf
HCV and Diabetes
Francesco Negro, University Hospitals of Geneva, Switzerland http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Negro HCV diabetes HepDART 2013.pdf
State of the Art Presentation
Epidemiology and Outcome of Viral Hepatitis B and C in the US
W. Ray Kim, Stanford University, USA http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Kim_MAC_Website.pdf





Breaking Down the Barriers to HCV Treatment among People Who Inject Drugs
Jason Grebely, University of New South Wales, Australia
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Grebely HEP DART 2013_06Dec13.pdf




Special Lecture: Off Label Combinations: Collaborative versus Incestuous
Donald Jensen, University of Chicago, USA
http://www.informedhorizons.com/hepdart2013/pdf/Presentations/Jensen_REVISED Off Label Combinations.pdf